Synlogic Inc (SYBX)

Synlogic received a Nasdaq delisting notice in November 2025 and plans to request a hearing. The share price declined by 18.18% from January 6, 2025, to January 2, 2026, and by 9.68% over the past six months as of January 6, 2026. The company discontinued its Phase 3 Synpheny-3 study for PKU, leading to a workforce reduction and strategic review. A reverse stock split occurred, and Synlogic reported its third-quarter 2024 financial results on November 13, 2024.

Information regarding demand seasonality for Synlogic, Inc.'s products and services is not directly available. As a clinical-stage biopharmaceutical company, its revenue is primarily derived from collaboration and grant revenue rather than product sales. Demand for its pipeline candidates is driven by the progression of clinical trials and regulatory approvals, rather than seasonal consumer patterns.

Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on developing Synthetic Biotic medicines for serious diseases, particularly rare metabolic and inflammatory conditions, and cancer. Their approach involves genetically engineering living probiotics to create oral biotherapeutics. Key product candidates include labafenogene marselecobac (SYNB1934) for PKU, SYNB1353 for HCU, SYNB8802 for enteric hyperoxaluria, and SYNB2081 for gout, with early-stage research in cystinuria and IBD. The Phase 3 study for labafenogene marselecobac (SYNB1934) was discontinued in early 2024.

Synlogic, Inc. is headquartered in Cambridge and Winchester, Massachusetts, and primarily operates in the United States.

Synlogic's brand reputation has been negatively impacted by the discontinuation of its Phase 3 study for PKU, a workforce reduction, and a strategic review. The Nasdaq delisting notice further indicates a challenging period for its reputation, overshadowing its history of pioneering synthetic biotic medicines and collaborations.

Synlogic, Inc. has a mixed ownership structure, with institutional investors holding over 64% of the stock as of late 2025. Major institutional owners include Cable Car Capital LLC, NEA Management Company, LLC, and Vanguard Group Inc. Major individual owners (insiders) include Peter W. Sonsini, Forest Baskett, and Scott D. Sandell. Ginkgo Bioworks Inc is also listed as an insider with significant ownership.